EA201892413A1 - Стабилизированные препараты гликопептидного антибиотика - Google Patents

Стабилизированные препараты гликопептидного антибиотика

Info

Publication number
EA201892413A1
EA201892413A1 EA201892413A EA201892413A EA201892413A1 EA 201892413 A1 EA201892413 A1 EA 201892413A1 EA 201892413 A EA201892413 A EA 201892413A EA 201892413 A EA201892413 A EA 201892413A EA 201892413 A1 EA201892413 A1 EA 201892413A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glyopeptid
stabilized
antibiotic preparations
antibiotic
infusion solutions
Prior art date
Application number
EA201892413A
Other languages
English (en)
Inventor
Сабина Кесер
Ивона Ясприца
Жером Ле-Кунфф
Original Assignee
Кселлия Фармасьютикалз Апс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кселлия Фармасьютикалз Апс filed Critical Кселлия Фармасьютикалз Апс
Publication of EA201892413A1 publication Critical patent/EA201892413A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В заявке описаны жидкие композиции на основе гликопептидных антибиотиков или их фармацевтически приемлемых солей, при этом гликопептидный антибиотик выбран из ванкомицина, телаванцина, оритаванцина, тейкопланина и далбаванцина. Указанные композиции подходят в качестве инфузионных растворов или в качестве концентрата для приготовления инфузионных растворов.
EA201892413A 2016-05-09 2017-05-04 Стабилизированные препараты гликопептидного антибиотика EA201892413A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333357P 2016-05-09 2016-05-09
PCT/EP2017/060653 WO2017194385A1 (en) 2016-05-09 2017-05-04 Stabilized glycopeptide antibiotic formulations

Publications (1)

Publication Number Publication Date
EA201892413A1 true EA201892413A1 (ru) 2019-05-31

Family

ID=58745200

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892413A EA201892413A1 (ru) 2016-05-09 2017-05-04 Стабилизированные препараты гликопептидного антибиотика

Country Status (20)

Country Link
US (1) US10729708B2 (ru)
EP (1) EP3454883A1 (ru)
JP (1) JP6946343B2 (ru)
KR (1) KR20190005940A (ru)
CN (1) CN109069580A (ru)
AR (1) AR109454A1 (ru)
AU (1) AU2017262943B2 (ru)
BR (1) BR112018072948A2 (ru)
CA (1) CA3021935A1 (ru)
CL (1) CL2018003147A1 (ru)
CO (1) CO2018011701A2 (ru)
EA (1) EA201892413A1 (ru)
IL (1) IL262796A (ru)
JO (2) JOP20170111B1 (ru)
MX (1) MX2018013584A (ru)
SA (1) SA518400392B1 (ru)
SG (1) SG11201809908TA (ru)
TW (2) TWI769694B (ru)
UY (1) UY37233A (ru)
WO (1) WO2017194385A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170234A (es) 2014-11-06 2018-01-15 Xellia Pharmaceuticals Aps Composiciones de antibiótico
WO2021231361A1 (en) * 2020-05-11 2021-11-18 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing active metabolites of remdesivir for inhalation
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤
WO2023211501A1 (en) * 2022-04-26 2023-11-02 Hikma Pharmaceuticals Usa Inc. Stable, ready-to-administer aqueous formulations of dalbavancin
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
WO2024079223A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1278549A (en) * 1916-12-16 1918-09-10 J E Simmons Nut and bolt lock.
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
US4885275A (en) 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
AU1407197A (en) * 1995-12-01 1997-06-19 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
WO2001083521A2 (en) 2000-05-02 2001-11-08 Theravance, Inc. Reductive alkylation process on glycopeptides
ATE416791T1 (de) 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
UA82824C2 (ru) * 2000-06-21 2008-05-26 К'Юбіст Фармасьютікалз, Інк. Композиция и способ улучшения перорального всасывания противомикробных средств
UA75083C2 (ru) 2000-06-22 2006-03-15 Тераванс, Інк. Производные гликопептидфосфонатов
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
BRPI0415637A (pt) 2003-10-31 2006-12-12 Univ Kansas derivados de sulfoalquil éter-alquil éter ciclodextrina
ES2482700T3 (es) 2005-02-14 2014-08-04 Venus Remedies Limited Terapia de combinación parenteral para enfermedades infecciosas causadas por una bacteria resistente a los medicamentos
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
CA2699550C (en) 2007-09-12 2020-08-18 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102755629A (zh) * 2012-08-02 2012-10-31 上海瑞创医药科技有限公司 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
CR20170234A (es) * 2014-11-06 2018-01-15 Xellia Pharmaceuticals Aps Composiciones de antibiótico
EP3302494A4 (en) 2016-01-08 2019-01-23 Gufic Biosciences Limited FREEZE-DRIED PARENTERAL COMPOSITION OF TIGECYCLIN AND METHOD FOR THE MANUFACTURE THEREOF
EP3416672A4 (en) * 2016-02-18 2019-09-18 Melinta Therapeutics, Inc. ORITAVANCINE FORMULATIONS

Also Published As

Publication number Publication date
TW201740955A (zh) 2017-12-01
SG11201809908TA (en) 2018-12-28
US20190175632A1 (en) 2019-06-13
CA3021935A1 (en) 2017-11-16
WO2017194385A1 (en) 2017-11-16
SA518400392B1 (ar) 2022-05-09
BR112018072948A2 (pt) 2019-02-19
CO2018011701A2 (es) 2019-02-08
AR109454A1 (es) 2018-12-12
KR20190005940A (ko) 2019-01-16
TWI769694B (zh) 2022-07-01
JP2019518733A (ja) 2019-07-04
JOP20170111B1 (ar) 2022-03-14
CL2018003147A1 (es) 2018-12-28
UY37233A (es) 2018-01-02
JP6946343B2 (ja) 2021-10-06
AU2017262943B2 (en) 2020-05-14
IL262796A (en) 2018-12-31
CN109069580A (zh) 2018-12-21
JOP20220039A1 (ar) 2023-01-30
EP3454883A1 (en) 2019-03-20
TWI772296B (zh) 2022-08-01
TW202133875A (zh) 2021-09-16
US10729708B2 (en) 2020-08-04
MX2018013584A (es) 2019-04-01
AU2017262943A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
EA201892413A1 (ru) Стабилизированные препараты гликопептидного антибиотика
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
EP3980400A4 (en) PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS
EA201890736A1 (ru) Модуляторы корового белка вируса гепатита b
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
EA201891988A1 (ru) Ингибиторы mcl-1 на основе замещенных индолов
WO2017023933A3 (en) Peptidomimetic macrocycles
MX2023002507A (es) Inhibidores de cd73.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
EP3731846A4 (en) DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTIONS
MX2015015506A (es) Peptidos antimicrobianos.
MX2018006190A (es) Antibioticos de amplio espectro macrociclico.
WO2019032936A8 (en) LINCONSAMIDE ANTIBIOTICS AND USES THEREOF
BR112018010267A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112016023899A2 (pt) composições compreendendo derivados de osteopontina para a inibição do crescimento do cabelo
EP4275759A3 (en) Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer
WO2017048699A3 (en) Highly potent monoclonal antibodies to angiogenic factors
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
EP3793539A4 (en) COMPOUNDS FOR THE TREATMENT OF DENGUE VIRUS INFECTIONS AND OTHER INFECTIONS
WO2018170236A9 (en) CDPK1 INHIBITORS, COMPOSITIONS AND RELATED METHODS
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
EP3893740A4 (en) BLOOD FLOW RESTRICTION SYSTEM
WO2014176068A3 (en) Treatment and prevention of bacterial skin infections using oritavancin
EA202191343A1 (ru) Антибиотические соединения, способы их получения, фармацевтические композиции, содержащие их, и их применение
MX2016011420A (es) Peptidos horquilla beta con propiedades antivirales contra el virus dengue.